L'Oreal

L'Oreal is the largest cosmetics company on the planet by a wide margin — €43.5B revenue in 2025, 37 international brands, sold in 150 countries. But the equity story in 2026 is not about scale. It is about whether the China consumer-recovery story, the Active-Cosmetics dermatology boom (CeraVe, La Roche-Posay, Vichy growing 12%+), and the luxury-fragrance arms race can re-accelerate growth back into double digits after a flat 2025.

The Bettencourt-Meyers family controls roughly 35% of voting rights through Téthys SAS, and Nestlé — once a 23% shareholder — has been quietly trimming since 2022. That ownership structure makes L'Oreal one of the few European mega-caps with genuine founder-aligned capital allocation: capex stays disciplined, dividends grow yearly, buybacks are opportunistic — not announced for show.

The catalyst nobody is pricing in: the 2026 Hainan duty-free recovery. China travel retail collapsed in 2024, costing L'Oreal an estimated 4 points of organic growth. Q2/2026 commentary suggests a slow rebound — and at 24x forward earnings, the stock has stopped discounting that story. Either it materializes — or the multiple compresses to the 18x where peers like Beiersdorf trade.

The Bettencourt family (Téthys SAS) is the anchor — roughly 35% voting rights, 100-year time horizon, never sold a single share since the 1957 inheritance settlement. Nestlé still holds 20.1% after selling 4% in 2014 and 4% in 2021 — and analysts increasingly see those Nestlé tranches as a recurring overhang every 5 to 7 years.

On the active-manager side, Fundsmith (Terry Smith) added L'Oreal to its top 10 in late 2024 and has held since — citing it as a textbook quality-compounder with structural pricing power. Lindsell Train also runs a sizable position. Both managers explicitly cited the family-control structure as a downside-protection feature, not a governance flag.

At €358.9 the stock trades at 31x trailing earnings and 24.4x forward — a clear premium to historic 22x average and to all European staples peers. The math only works if (a) 2026 organic growth re-accelerates to 5%+ and (b) operating margin holds at 20%. The bull case prints €18.50 EPS in 2027 — that puts forward PE at 19x, which is closer to fair value. The bear case (China stays soft, Estée wins back share) prints €15.50 EPS — and a re-rating to 18x means €280 per share, about 22% downside from here.

Dividend yield of 2.01% is well-covered (33% payout ratio) but unlikely to attract income investors at this multiple. FCF of €5.9B supports roughly €1.5B buybacks per year — meaningful but not market-moving against a €192B market cap.

1. Feb 6, 2026: FY2025 full-year results — first read on 2026 organic-growth guidance and China travel-retail commentary
2. Apr 22, 2026: Q1/2026 sales — Hainan duty-free recovery confirmation and pricing-versus-volume mix
3. Sep 2026: Active Cosmetics Capital Markets Day — first formal margin and growth targets for CeraVe through 2030

My view: L'Oreal is the cleanest quality-compounder in European staples — but the entry price matters. At 24x forward I would not chase. I am building a position only if it pulls back to the €310-320 range, which would be 21x forward and gives me a margin of safety against the Estée-recapture and EUR-strength scenarios. For long-term holders already in the stock, this is a hold, not a sell — the compounding engine is intact, the family-control structure is a feature not a bug, and Active Cosmetics is still in the early innings.

The smart-money signal that matters most: Fundsmith and Lindsell Train both added — not trimmed — through 2024-2025. When quality-only managers sit through a 20% drawdown without selling, the long-term thesis is intact.